Fatar M, Stroick M, Griebe M, Hennerici M (2005) Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 20:141–151.
Gidday JM, Gasche YG, Copin JC, Shah AR, Perez RS, Shapiro SD, Chan PH,
Park TS (2005) Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol
289:H558 –H568.
Gottschall PE, Deb S (1996) Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation
3:69 –75.
Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA
(2005) A highly specific inhibitor of matrix metalloproteinase-9 rescues
laminin from proteolysis and neurons from apoptosis in transient focal
cerebral ischemia. J Neurosci 25:6401– 6408.
Harkness KA, Adamson P, Sussman JD, Davies-Jones GA, Greenwood J,
Woodroofe MN (2000) Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 123:698 –709.
Hedtjarn M, Leverin AL, Eriksson K, Blomgren K, Mallard C, Hagberg H
(2002) Interleukin-18 involvement in hypoxic–ischemic brain injury.
J Neurosci 22:5910 –5919.
Hedtjarn M, Mallard C, Hagberg H (2004) Inflammatory gene profiling in
the developing mouse brain after hypoxia-ischemia. J Cereb Blood Flow
Metab 24:1333–1351.
Hedtjarn M, Mallard C, Iwakura Y, Hagberg H (2005) Combined deficiency
of IL-1beta18, but not IL-1alphabeta, reduces susceptibility to hypoxiaischemia in the immature brain. Dev Neurosci 27:143–148.
Jiang X, Namura S, Nagata I (2001) Matrix metalloproteinase inhibitor KB- R7785 attenuates brain damage resulting from permanent focal cerebral
ischemia in mice. Neurosci Lett 305:41– 44.
Lefebvre V, Peeters-Joris C, Vaes G (1991) Production of gelatin-degrading
matrix metalloproteinases (“type IV collagenases”) and inhibitors by ar- ticular chondrocytes during their dedifferentiation by serial subcultures
and under stimulation by interleukin-1 and tumor necrosis factor alpha.
Biochim Biophys Acta 1094:8 –18.
Liu XH, Kwon D, Schielke GP, Yang GY, Silverstein FS, Barks JD (1999)
Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic-ischemic brain damage. J Cereb Blood Flow Metab
19:1099 –1108.
Lohmann C, Krischke M, Wegener J, Galla HJ (2004) Tyrosine phosphatase
inhibition induces loss of blood-brain barrier integrity by matrix
metalloproteinase-dependent and -independent pathways. Brain Res
995:184 –196.
Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human
central nervous system, microglial nodules, and multiple sclerosis lesions.
J Neuropathol Exp Neurol 55:300 –309.
Mannello F, Luchetti F, Falcieri E, Papa S (2005) Multiple roles of matrix
metalloproteinases during apoptosis. Apoptosis 10:19 –24.
McRae A, Gilland E, Bona E, Hagberg H (1995) Microglia activation after
neonatal hypoxic-ischemia. Brain Res Dev Brain Res 84:245–252.
Mun-Bryce S, Rosenberg GA (1998) Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol
274:R1203–R1211.
Muramatsu K, Fukuda A, Togari H, Wada Y, Nishino H (1997) Vulnerability to cerebral hypoxic-ischemic insult in neonatal but not in adult rats is
in parallel with disruption of the blood-brain barrier. Stroke 28:2281–
2288; discussion 2288 –2289.
Okada Y, Tsuchiya H, Shimizu H, Tomita K, Nakanishi I, Sato H, Seiki M,
Yamashita K, Hayakawa T (1990) Induction and stimulation of 92-kDa
gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor alpha. Biochem Biophys Res
Commun 171:610 – 617.
